Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,607 people get SGEN articles and Market Currents by email alert.
Get email alerts on SGEN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (May 14, 2013)
-
Business Wire (May 9, 2013)
-
-
Business Wire (May 7, 2013)
-
-
-
-
Business Wire (Feb 27, 2013)
-
-
-
Business Wire (Feb 12, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Seattle Genetics at ASH 2007 (Part III)Ohad Hammer • Wed, Dec 26, 2007
-
Seattle Genetics at ASH 2007 (Part II)Ohad Hammer • Sun, Dec 23, 2007
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Casey Analyst Forecasts Explosive Biotech GrowthLife Sciences Report • Thu, Oct 11, 2012 -
-
-
-
-
-
7 Low-Debt Mid-Cap Stocks Flush With Cash ReservesZetaKap • Thu, Aug 23, 2012 -
-
Seattle Genetics, Inc. Q2 2010 Earnings Call TranscriptTue, Jul 27, 2010
-
Seattle Genetics Inc. Q1 2010 Earnings Call TranscriptSat, May 1, 2010
-
Seattle Genetics Inc. Q2 2009 Earnings Call TranscriptThu, Jul 23, 2009
-
Seattle Genetics Inc. Q1 2009 Earnings Call TranscriptThu, Apr 23, 2009 • 1 Comment
-
Seattle Genetics, Inc. Q4 2008 Earnings Call TranscriptWed, Feb 11, 2009
-
Seattle Genetics, Inc. Q3 2008 Earnings Call TranscriptFri, Oct 24, 2008
-
Seattle Genetics Inc. Q2 2008 Earnings Call TranscriptTue, Jul 22, 2008
-
Seattle Genetics Inc. Q1 2008 Earnings Call TranscriptFri, Apr 25, 2008
-
Seattle Genetics Inc. Q4 2007 Earnings Call TranscriptTue, Feb 19, 2008
-
Seattle Genetics Q3 2007 Earnings Call TranscriptFri, Oct 26, 2007
-
Business Wire (May 14, 2013)
-
Business Wire (May 9, 2013)
-
Business Wire (May 7, 2013)
-
at CNBC.com (Apr 16, 2013)
-
at CNBC.com (Apr 4, 2013)
-
Business Wire (Feb 27, 2013)
-
Business Wire (Feb 12, 2013)
-
Business Wire (Feb 6, 2013)
-
Business Wire (Jan 25, 2013)
-
at CNBC.com (Jan 9, 2013)
-
Business Wire (Jan 3, 2013)
-
Business Wire (Dec 11, 2012)
SGEN vs. ETF Alternatives
Company Description
Seattle Genetics is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. We initiated a pivotal trial of our lead product candidate, SGN-35, during the first quarter of... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 7, 4:10 PM Seattle Genetics (SGEN): Q1 EPS of -$0.14 beats by $0.05. Revenue of $57.3M beats by $3.58M. Shares +8.9% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
- Tuesday, May 7, 12:10 AM Notable earnings after Tuesday’s close: ANDE, ARAY, AWK, AXLL, BIO, BIOL, BMC, BWC, CA, CDXS, CHRW, CODI, DGI, DGIT, DIS, DVA, EA, ENPH, EXEL, GA, GPOR, HTA, IAG, JAZZ, KGC, LYV, MAKO, MCEP, MCK, MDLZ, MITK, MRO, MYGN, NVTL, OAS, OCLR, OHI, ONXX, ORA, PRI, RBCN, SD, SGEN, SYMC, SYNC, TRIP, TWO, URS, VCLK, WBMD, WFM, WMB, WPZ, WTI, Z 1 Comment [Earnings]
- Monday, May 6, 5:35 PM Notable earnings after Tuesday’s close: ANDE, ARAY, AWK, AXLL, BIO, BIOL, BMC, BWC, CA, CDXS, CHRW, CODI, DGI, DGIT, DIS, DVA, EA, ENPH, EXEL, GTEK, GA, GPOR, IAG, JAZZ, KGC, LYV, MAKO, MCEP, MCK, MDLZ, MITK, MRO, MYGN, NVTL, OAS, OCLR, OHI, ONXX, ORA, PRI, RBCN, SD, SGEN, SYMC, SYNC, TRIP, TWO, URS, VCLK, WBMD, WFM, WMB, WPZ, WTI, Z 1 Comment [Earnings]
-
Wednesday, February 13, 5:54 PM
After-hours top gainers, as of 5:15 p.m.: ANGI +21%. BCOR +12%. JCOM +7%. VCLK +6%. SGEN +5%.
After-hours top losers: STMP -24%. NSPH -22%. WTW -16%. CTL -16%. ITRI -10%. Comment! [On the Move] - Tuesday, February 12, 5:21 PM More on Seattle Genetics (SGEN): Q4 beats across the board on a 30% jump in total sales. Bottom line numbers were boosted by higher Adcetris sales and lower SG&A expenses, but were offset somewhat by higher R&D costs. Shares +0.6% AH. Comment! [Earnings, Healthcare]
- Tuesday, February 12, 4:47 PM More on Seattle Genetics (SGEN): Q4 beats across the board on a 30% jump in total sales. Bottom line numbers were boosted by higher Adcetris sales and lower SG&A expenses, but were offset somewhat by higher R&D costs. Shares +0.6% AH. Comment! [Healthcare, Earnings]
- Tuesday, February 12, 4:19 PM Seattle Genetics (SGEN): Q4 EPS loss of $0.09 beats by $0.02. Revenue of $63.9M beats by $6.7M. (PR). Comment! [Healthcare, Earnings, Breaking News]
- Tuesday, February 12, 12:10 AM Notable earnings after Tuesday’s close: ACC, AXLL, BWLD, CLF, CLWR, DDR, FRT, FTI, HTS, LPSN, NRP, NTGR, RAX, RENN, RKUS, SCI, SGEN, SKT, SVM, THRX, TRLA, WU, XNPT 1 Comment [Earnings]
- Monday, February 11, 5:35 PM Notable earnings after Tuesday’s close: ACC, AXLL, BWLD, CLF, CLWR, DDR, FRT, FTI, HTS, LPSN, NRP, NTGR, RAX, RENN, RKUS, SCI, SGEN, SKT, SVM, THRX, TRLA, WU, XNPT 1 Comment [Earnings]
- Friday, February 1, 3:53 PM Seattle Genetics (SGEN +0.5%) says that Health Canada has approved Adcetris for the treatment of patients with either Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Comment! [Healthcare, Global & FX]
- Monday, December 10, 2012, 9:01 AM Celldex (CLDX) jumps 9.6% after saying its CDX-011 drug delayed tumor growth and extended the survival of patients with advanced breast cancer compared with those who received single-agent chemotherapy in a Phase II trial. Seattle Genetics (SGEN) also has an interest in the drug. Celldex now hopes to persuade the FDA to authorize a confirmatory study of CDX-011, which could lead to accelerated approval. (PR) 1 Comment [Healthcare, On the Move]
- Monday, November 26, 2012, 9:36 AM The FDA grants orphan drug designation to Seattle Genetics' (SGEN) Adcetris for the treatment of mycosis fungoides, the most common form of cutaneous T-cell lymphoma, which is a class of non-Hodgkin's lymphoma. Seattle Genetics is developing Adcetris in combination with Millennium: The Takeda Oncology Company; the drug is in Phase III trials. (PR) Comment! [Healthcare]
-
Thursday, November 8, 2012, 9:10 AM
Premarket gainers: DUSA +38%. MTSL +28%. USAT +15%. WLL +11%. ITMN +11%. SD +9%. QCOM +9%. THQI +8%. EZCH +7%. ALU +6%. MWW +7%. TTM +6%. DF +5%.
Losers: CPRX -56%. BCRX -34%. PANL -25%. SVNT -19%. SGEN -11%. MNST -10%. CNQR -9%. TNK -9%. NBG -8%. PSTI -8%. MAKO -7%. WINI -6%. AUI -5%. Comment! [On the Move] - Wednesday, November 7, 2012, 4:17 PM Seattle Genetics (SGEN): Q3 EPS of -$0.12 beats by $0.03. Revenue of $49.8M (+145% Y/Y) misses by $3M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, November 7, 2012, 12:10 AM Notable earnings after Wednesday’s close: ARAY, ATO, ATVI, AWK, BONE, CBS, CLR, CODI, CPE, CPNO, CTL, CXO, ETE, ETP, EXEL, FTK, GMXR, GSS, HIMX, HNSN, ITMN, KGC, MAKO, MBI, MDLZ, MNST, MWE, NQ, OAS, ONTY, OSUR, PAAS, PANL, PRI, PRU, QCOM, SGEN, SLXP, SNTS, SRZ, SSRI, SXL, TCAP, TIE, TS, WFM Comment! [Earnings]
- Tuesday, November 6, 2012, 5:35 PM Notable earnings after Wednesday’s close: ARAY, ATO, ATVI, AWK, BONE, CBS, CLR, CODI, CPE, CPNO, CTL, CXO, ETE, ETP, EXEL, FTK, GMXR, GSS, HIMX, HNSN, ITMN, KGC, MAKO, MBI, MDLZ, MNST, MWE, NQ, OAS, ONTY, OSUR, PAAS, PANL, PRI, PRU, QCOM, SGEN, SLXP, SNTS, SRZ, SSRI, SXL, TCAP, TIE, TS, WFM Comment! [Earnings]
-
The Wall Street Transcript
Celldex Therapeutics ($CLDX) Utilizes Seattle Genetics ($SGEN) Technology to Target Novel Receptor in Breast Cancer- http://su.pr/2Axyu7 - View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Jim Van Meerten
SGEN - 60% Barchart short term technical sell signal - 23.57% below its 1 year high - Relative Strength Index 31.96% and falling - View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 1 replies
-